Startseite/Aktien/CGEM

CGEM

USD

Cullinan Therapeutics Inc. Common Stock

$7.400-0.400 (-5.128%)

Echtzeitkurs

Healthcare

Biotechnologie

Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$7.800

Hoch

$7.800

Tief

$7.360

Volumen

0.61M

Unternehmensfundamentaldaten

Marktkapitalisierung

437.2M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.89M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $5.68Aktuell $7.400Hoch $17.503

Ähnliche Nachrichten

3. Nov. 2025 · 14:11

GlobeNewswire

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

25. Okt. 2025 · 15:01

GlobeNewswire

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a clinical-stage